Search research articles
Contact Us
Filters
Showing results (241-250 of 271) with videos related to
Page
of 28
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2021
Hematological immune related adverse events after treatment with immune checkpoint inhibitors
Rafaela Kramer, Anne Zaremba, Alvaro Moreira, et al.
Journal for Immunotherapy of Cancer
|
June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma
James William Smithy, Allison Betof, Sebastian Klobuch, et al.
JAMA Oncology
|
September 23, 2018
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
Daniel Y Wang, Joe-Elie Salem, Justine V Cohen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2022
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment
Georg C Lodde, Philipp Jansen, Inga Möller, et al.
Cancers
|
February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma
Michael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
Data in Brief
|
November 25, 2022
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
Nature Medicine
|
July 13, 2026
An anti-PMEL antibody-drug conjugate with a G<sub>q/1</sub><sub>1</sub> inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial
Matteo S Carlino, Ellen Kapiteijn, Sophie Piperno-Neumann, et al.
The New England Journal of Medicine
|
June 8, 2010
Improved survival with ipilimumab in patients with metastatic melanoma
F Stephen Hodi, Steven J O'Day, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2019
Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations
Christian Menzer, Alexander M Menzies, Matteo S Carlino, et al.
Page
of 28
Search research articles
Search
Showing results (241-250 of 271) with videos related to
Sort By:
Page
of 28
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2021
Hematological immune related adverse events after treatment with immune checkpoint inhibitors
Rafaela Kramer, Anne Zaremba, Alvaro Moreira, et al.
Journal for Immunotherapy of Cancer
|
June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma
James William Smithy, Allison Betof, Sebastian Klobuch, et al.
JAMA Oncology
|
September 23, 2018
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
Daniel Y Wang, Joe-Elie Salem, Justine V Cohen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2022
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment
Georg C Lodde, Philipp Jansen, Inga Möller, et al.
Cancers
|
February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma
Michael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
Data in Brief
|
November 25, 2022
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
Nature Medicine
|
July 13, 2026
An anti-PMEL antibody-drug conjugate with a G<sub>q/1</sub><sub>1</sub> inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial
Matteo S Carlino, Ellen Kapiteijn, Sophie Piperno-Neumann, et al.
The New England Journal of Medicine
|
June 8, 2010
Improved survival with ipilimumab in patients with metastatic melanoma
F Stephen Hodi, Steven J O'Day, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2019
Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations
Christian Menzer, Alexander M Menzies, Matteo S Carlino, et al.
Page
of 28